Japan Cell, Regenerative Therapy Environment ‘Exciting’ But Ongoing Dialog Needed
While the environment for cell and regenerative medicines in Japan is ‘exciting’ and positive, ongoing dialog with policy makers and regulators is needed to ensure a reflection of industry and patient concerns, one CEO says.
You may also be interested in...
Novartis CAR-T therapy becomes most expensive drug ever covered by Japan’s national health insurance system. Although authorities expect total sales to be modest, might high price again raise official concerns over ballooning health costs?
Activity in Japan's cell and regenerative therapy space continues apace as venture starts trial with lead development asset for acute respiratory distress syndrome.
The head of Japan’s drug and device regulator has defended and supported the country’s recent world-first decision to grant approval to a novel cell-based therapy for spinal cord injuries, saying that patient considerations came first.